Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Approves Gemtuzumab Ozogamicin for CD33+ Pediatric AML

June 16th 2020

The US Food and Drug Administration has extended the indication of gemtuzumab ozogamicin (Mylotarg) for newly diagnosed CD33-positive acute myeloid leukemia to include pediatric patients 1 month and older.

Dr. Lee on Examining Novel Targets in Lymphomas and Leukemias

June 15th 2020

Hun Ju Lee, MD, discusses novel targets in lymphomas and leukemias.

Isatuximab Triplet Significantly Improves PFS in Relapsed/Refractory Myeloma

June 14th 2020

The triplet therapy of isatuximab-irfc, carfilzomib, and dexamethasone showed a statistically significant improvement in PFS versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Endotheliopathy: A Marker of Progression to Critical Illness in COVID-19

June 14th 2020

Endotheliopathy represents a marker of progression to critical illness in patients with COVID-19 infection and soluble thrombomodulin segregates with mortality.

Ropeginterferon Alfa-2b Helps Maintain Hematocrit Control for Low-Risk Polycythemia Vera

June 14th 2020

More patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b were able to maintain hematocrit levels at or below 45% compared with those who received monthly phlebotomy alone.

Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia

June 14th 2020

Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.

Dr. Talati on Real-World Data With Venetoclax Combinations in AML

June 13th 2020

Chetasi Talati, MD, discusses the ongoing safety analysis of venetoclax (Venclexta)-based combinations in patients with newly diagnosed acute myeloid leukemia.

Dr. Cluzeau on the Efficacy of APR-246/Azacitidine in TP53-Mutated MDS and AML

June 13th 2020

Thomas Cluzeau, MD, PhD, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Adding Subcutaneous Daratumumab to CyBorD Improves Outcomes for AL Amyloidosis

June 13th 2020

Subcutaneous daratumumab may be a promising treatment for newly diagnosed patients with light chain amyloidosis who are in urgent need of new treatment options.

Venetoclax/Azacitidine Showcases OS Benefit in Older Patients With AML

June 13th 2020

The combination of venetoclax (Venclexta) and azacitidine led to a 34% reduction in the risk of death versus azacitidine alone in treatment-naïve patients with acute myeloid leukemia who are ineligible for intensive therapy.

Liso-Cel Induces High Response Rates in High-Risk Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

June 12th 2020

Treatment with the CAR T-cell product lisocabtagene maraleucel led to high response rates, with durable complete responses, in transplant-ineligible patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma who had poor prognostic features.

Dr. Hari on the Role of MRD in Multiple Myeloma

June 12th 2020

Parameswaran Hari, MD, MRCP, discusses the role of minimal residual disease in multiple myeloma.

Dr. Costa on Safety of CC-93269 in Relapsed/Refractory Myeloma

June 12th 2020

Luciano J. Costa, MD, PhD, discusses the safety results of CC-93269 in patients with relapsed/refractory multiple myeloma.

Dr. Abdulhaq on the Safety Profile of Tafasitamab in DLBCL

June 12th 2020

Haifaa Abdulhaq, MD, discusses the safety profile of tafasitamab (MOR208) in diffuse large B-cell lymphoma.

Dr. Kahl on Findings From the L-MIND Study With Tafasitamab in DLBCL

June 12th 2020

Brad S. Kahl, MD, discusses findings from the phase 2 L-MIND study in diffuse large B-cell lymphoma.

Dr. Flinn on the Utility of Tafasitamab in Relapsed/Refractory DLBCL

June 12th 2020

Ian W. Flinn, MD, PhD, discusses the utility of tafasitamab (MOR208) in patients with relapsed diffuse large B-cell lymphoma (DLBCL).

Serum Biomarkers Are Early Predictors for Haplo-SCT Outcomes

June 12th 2020

Higher levels of the serum biomarkers ST2 and REG3α were associated with increased incidence of graft-vs-host disease and increased risk for transplant-related mortality in patients who have undergone haploidentical stem-cell transplantation with post-transplant cyclophosphamide.

Pegcetacoplan Outperforms Current Standard of Care in Paroxysmal Nocturnal Hemoglobinuria

June 12th 2020

The novel C3 inhibitor pegcetacoplan led to a significant improvement in hemoglobin level and other clinical outcomes at week 16 versus the current standard of care, eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Ruxolitinib Improves Outcomes in aGVHD Across Subgroups

June 12th 2020

Ruxolitinib (Jakafi) induced a strong, durable response across several subgroups of patients with steroid-refractory acute graft-versus-host disease.

Omitting Radiation Does Not Reduce Survival for Patients with Early Unfavorable HL

June 12th 2020

Radiation therapy can be omitted in patients with newly diagnosed early-stage unfavorable Hodgkin lymphoma without sacrificing efficacy.